• About us
• Contact

Advertisement

Organisation › Details

Caraway Therapeutics Inc.

Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating lysosomal function. Caraway is utilizing its unique product engine to develop proprietary insights into lysosomal function and small molecule ion channel modulation and advance a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The company is backed by top-tier investors, including SV Health Investors and its Dementia Discovery Fund, AbbVie Ventures, MRL Ventures Fund, Amgen Ventures, and Eisai Innovation. *

 

	Start	2019-10-10 renamed
	Group	Merck (US) (MSD) (Group)
	Predecessor	Rheostat Therapeutics Inc.
	Industry	pharmaceutical
	Industry 2	small-molecule drug
	Person	Harris, Tim (Bioverativ 201709 EVP RnD)
	Person 2	Hyman, Anthony (Tony) (Max Planck 201901 Group Leader at MPI-CBG Dresden + Co-Founder Dewpoint Therapeutics)
	Region	Cambridge, MA
	Country	United States (USA)
	Street	300 Technology Square Floor 2
	City	02139 Cambridge, MA
		Address record changed: 2023-11-22
Basic data	Employees	n. a.
		* Document for »About Section«: Merck & Co., Inc.. (11/21/23). "Press Release: Merck to Acquire Caraway Therapeutics, Inc.". Rahway, NJ & Cambridge, MA.
		Record changed: 2023-11-23

Advertisement

More documents for Merck (US) (MSD) (Group)

• [1] N-Power Medicine, Inc.. (7/1/24). "Press Release: N-Power Medicine Emerges with Series B Funding to Bolster Access to Innovative Oncology Clinical Trials". Redwood City, CA....
• [2] N-Power Medicine, Inc.. (7/1/24). "Press Release: N-Power Medicine Collaborates with Merck to Expand Oncologist and Patient Access to Clinical Trials". Redwood City, CA....
• [3] Merck & Co., Inc.. (5/29/24). "Press Release: Merck to Acquire EyeBio". Rahway, NJ & New York, NY....
• [4] Merck & Co., Inc.. (1/8/24). "Press Release: Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline". Rahway, NJ & South San Francisco, CA....
• [5] Owkin. (12/19/23). "Press Release: Owkin Enters Collaboration Agreement with MSD to Develop AI-powered Diagnostics for Cancer"....
• [6] Merck & Co., Inc.. (11/21/23). "Press Release: Merck to Acquire Caraway Therapeutics, Inc.". Rahway, NJ & Cambridge, MA....
• [7] Merck & Co., Inc.. (11/20/23). "Press Release: Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference". Rahway, NJ....
• [8] Harpoon Therapeutics, Inc.. (10/23/23). "Press Release: Harpoon Therapeutics Announces up to $150 Million Private Placement". South San Francisco, CA....
• [9] Merck & Co., Inc.. (10/19/23). "Press Release: Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs". Basking Ridge, NJ & Rahway, NJ....
• [10] AiCuris Anti-infective Cures AG. (8/23/23). "Press Release: AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of Prevymis (letermovir) in Second Indication". Wuppertal....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.